Cochrane · systematic review · CD012815
Marine‐derived n‐3 fatty acids therapy for stroke
Alvarez Campano, CG, Macleod, MJ, Aucott, L, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
12
No studies
2
Included studies
NR
No studies 2 · 14.3%Ungraded 0 · 0%Very low 5 · 35.7%Low 7 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyMarine‐derived n‐3 fatty acids therapy compared to no marine‐derived n‐3 fatty acids therapy for stroke: short follow‐up (three months or less)
Population: stroke and/or TIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: efficacy (functional outcome) Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | RR 0.78 [0.36, 1.68] | 1 study · 40 participants | Very low Downgraded: risk of bias |
Vascular‐related death Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 2 studies · 142 participants | Low Downgraded: risk of bias, imprecision |
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | RR 0.41 [0.02, 8.84] | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
Incidence of other type of stroke (ischaemic or haemorrhagic): fatal or non‐fatal Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 2 studies · 58 participants | Very low Downgraded: risk of bias |
Adverse events Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 2 studies · 57 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 102 participants | Low Downgraded: risk of bias, imprecision |
Mood Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 102 participants | Low Downgraded: risk of bias, imprecision |
Marine‐derived n‐3 fatty acids therapy compared to no marine‐derived n‐3 fatty acids therapy for stroke: follow‐up longer than three months
Population: stroke and/or TIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Primary outcome: Efficacy (functional outcome) Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 52 participants | Very low Downgraded: risk of bias |
Vascular‐related death Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | RR 1.02 [0.78, 1.35] | 5 studies · 2237 participants | Low Downgraded: risk of bias, imprecision |
Recurrent events (both ischaemic and haemorrhagic stroke) Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | RR 0.69 [0.31, 1.55] | 3 studies · 1819 participants | Low Downgraded: risk of bias, imprecision |
Incidence of other type of stroke ‒ not measured Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | NR | No studies |
Adverse events Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | RR 0.94 [0.56, 1.58] | 1 study · 1455 participants | Low Downgraded: risk of bias, imprecision |
Quality of life ‒ not measured Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | NR | No studies |
Mood Marine‐derived n‐3 fatty acids therapy vs no marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 14 participants | Low Downgraded: risk of bias, imprecision |
Marine‐derived n‐3 fatty acids therapy compared to No marine‐derived n‐3 fatty acids therapy for stroke. Short follow‐up (three months or less)
Population: stroke and/or TIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy (functional outcome) Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | RR 0.78 [0.36, 1.68] | 1 study · 40 participants | Very low Downgraded: risk of bias |
Vascular‐related death Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 2 studies · 142 participants | Low Downgraded: risk of bias, imprecision |
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | RR 0.41 [0.02, 8.84] | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
Incidence of other type of stroke (ischaemic or haemorrhagic): fatal or non‐fatal Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 2 studies · 58 participants | Very low Downgraded: risk of bias |
Adverse events Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 2 studies · 57 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 102 participants | Low Downgraded: risk of bias, imprecision |
Mood Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 102 participants | Low Downgraded: risk of bias, imprecision |
Marine‐derived n‐3 fatty acids therapy compared to No marine‐derived n‐3 fatty acids therapy for stroke. Follow‐up longer than three months
Population: stroke and/or TIA
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Efficacy (functional outcome) Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 52 participants | Very low Downgraded: risk of bias |
Vascular‐related death Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | RR 1.02 [0.78, 1.35] | 5 studies · 2237 participants | Low Downgraded: risk of bias, imprecision |
Recurrent events (both ischaemic and haemorrhagic stroke) Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | RR 0.69 [0.31, 1.55] | 3 studies · 1819 participants | Low Downgraded: risk of bias, imprecision |
Incidence of other type of stroke ‒ not measured Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | NR | No studies |
Adverse events Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | RR 0.94 [0.56, 1.58] | 1 study · 1455 participants | Low Downgraded: risk of bias, imprecision |
Quality of life ‒ not measured Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | NR | No studies |
Mood Marine‐derived n‐3 fatty acids therapy vs No marine‐derived n‐3 fatty acids therapy | no estimate extracted | 1 study · 14 participants | Low Downgraded: risk of bias, imprecision |